Literature DB >> 19300873

How can we recognize "disease modification" effects?

E R Siemers1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19300873     DOI： 10.1007/s12603-009-0036-7

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN： 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  22 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

Review 2.  Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Authors:  Richard A Frank; Douglas Galasko; Harald Hampel; John Hardy; Mony J de Leon; Pankaj D Mehta; Joseph Rogers; Eric Siemers; John Q Trojanowski
Journal:  Neurobiol Aging       Date:  2003 Jul-Aug       Impact factor: 4.673

3.  Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Authors:  E R Siemers; J F Quinn; J Kaye; M R Farlow; A Porsteinsson; P Tariot; P Zoulnouni; J E Galvin; D M Holtzman; D S Knopman; J Satterwhite; C Gonzales; R A Dean; P C May
Journal:  Neurology       Date:  2006-02-28       Impact factor: 9.910

Review 4.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

5.  The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases.

Authors:  M C Tierney; R H Fisher; A J Lewis; M L Zorzitto; W G Snow; D W Reid; P Nieuwstraten
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

6.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

Review 7.  Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease.

Authors:  Brandy Matthews; Eric R Siemers; P David Mozley
Journal:  Am J Geriatr Psychiatry       Date:  2003 Mar-Apr       Impact factor: 4.105

8.  Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease.

Authors:  Richard C Mohs; Claudia Kawas; Maria C Carrillo
Journal:  Alzheimers Dement       Date:  2006-07       Impact factor: 21.566

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Authors:  N C Fox; R S Black; S Gilman; M N Rossor; S G Griffith; L Jenkins; M Koller
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910
View more
  12 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

2.  Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Authors:  M W Weiner
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 3.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Authors:  Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

4.  Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.

Authors:  Gary Tong; Lorna Castaneda; Jun-Sheng Wang; Oleksandr Sverdlov; Shu-Pang Huang; Randy Slemmon; Huidong Gu; Oi Wong; Hewei Li; Robert M Berman; Christina Smith; Charles Albright; Randy C Dockens
Journal:  Clin Drug Investig       Date:  2012-11       Impact factor: 2.859

Review 5.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Harald Hampel; Michael Weiner; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

Review 6.  Fluid biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Henrik Zetterberg; Anne M Fagan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

7.  Use of biomarkers in Alzheimer's trials.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

8.  Using biomarkers to improve detection of Alzheimer's disease.

Authors:  Milton C Biagioni; James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2011-04

9.  Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.

Authors:  Henrik Zetterberg; Niklas Mattsson; Kaj Blennow; Bob Olsson
Journal:  Alzheimers Res Ther       Date:  2010-11-30       Impact factor: 6.982

Review 10.  Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.

Authors:  Aaron Ritter; Jeffrey Cummings
Journal:  Front Neurol       Date:  2015-08-31       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.